t
Shield Therapeutics plc granted 1,547,262 share options to Group CEO Anders Lundstrom on 13 October 2025 under its Retention and Performance Share Plan. The options have an exercise price of 1.5p per share and will vest in three equal tranches over three years. These granted options constitute approximately 0.1% of the total AIM securities currently in issue.
| Date | 14 Oct 2025 |
| Time | 15:01:57 |
| Category | Director/PDMR dealings |
| ID | 3454D |
Shield Therapeutics plc
("Shield" or the "Company" or the "Group")
Grant of Share Options to Chief Executive Officer
London, UK, 14 October 2025: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company specialising in iron deficiency, announces that on 13 October 2025 it granted share awards in the form of options over ordinary shares in the capital of the Company ("Ordinary Shares") under Shield Therapeutics' Retention and Performance Share Plan ("RPSP") to the Group CEO as part of his 2025 annual equity grant.
In accordance with the requirements of the EU Market Abuse Regulations the following options have been granted to Anders Lundstrom, Chief Executive Officer, who is deemed a PDMR:
|
Name |
Option Plan |
Number of Ordinary Shares under Option |
Vesting Date |
|
Anders Lundstrom |
RPSP |
1,547,262 |
Three equal traches over three years from the date of grant, subject to Mr Lundstrom remaining in office as at the date of vesting. |
The proportion of total option awards to Anders Lundstrom is approximately 0.1% of the total number of AIM securities in issue at this time.
Anders Lundstrom currently holds 585,000 ordinary shares in the Company.
|
1. |
Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") |
|||||
|
a) |
Name |
Anders Lundstrom |
||||
|
2. |
Reason for the notification |
|||||
|
a) |
Position/status |
Chief Executive Officer
|
||||
|
b) |
Initial notification/ amendment |
Initial Notification |
||||
|
3. |
Details of the Issuer |
|||||
|
a) |
Name |
Shield Therapeutics plc |
||||
|
b) |
LEI code |
213800G74QWY15FC3W71 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument
Identification code |
Options over new Ordinary Shares
ISIN: GB00BYV81293 |
||||
|
b) |
Nature of the transaction |
Grant of awards over new Ordinary Shares under the Company's Retention and Performance Share Plan. |
||||
|
c) |
Price(s) and volumes(s) |
2025 RPSP Award
|
||||
|
d) |
Aggregated information - Aggregate volume
- Price |
Awards granted over 1,547,262 shares in total
1.5p exercise price |
||||
|
e) |
Date of the transaction |
13 October 2025 |
||||
|
f) |
Place of the transaction |
Outside of trading venue |
||||
For further information please contact:
|
Shield Therapeutics plc |
|
|
Anders Lundstrom, CEO Santosh Shanbhag, CFO Stephanie Hicks, Investor Relations |
+44 (0) 191 511 8500 |
|
Nominated Adviser and Joint Broker |
|
|
Peel Hunt LLP |
|
|
James Steel |
+44 (0)20 7418 8900 |
|
|
|
|
Joint Broker Cavendish Ltd Geoff Nash/ Isaac Hooper/Nigel Birks/Harriet Ward |
+44 (0)20 7220 0500 |
|
|
|
|
|
|
About Iron Deficiency and ACCRUFeR®/FeRACCRU®
Clinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR® has the potential to meet an important unmet medical need for both physicians and patients and is now the leading #1 branded prescription oral iron the market today (data source - IQVIA Xponent PlanTrak).
ACCRUFeR®/FeRACCRU® (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA. The drug has a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFeR®/FeRACCRU®, including the product label, can be found at: www.accrufer.com and www.feraccru.com.
About Shield Therapeutics plc
Shield is a commercial stage specialty pharmaceutical company that delivers ACCRUFeR®/FeRACCRU® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched ACCRUFeR® in the U.S. with an exclusive, multi-year collaboration agreement with Viatris. Outside of the U.S., the Company has licensed the rights to five specialty pharmaceutical companies. FeRACCRU® is commercialised in the UK and European Union by Norgine B.V., which also has marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of ACCRUFeR®/FeRACCRU® in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea, with Kye Pharmaceuticals Inc. for Canada, and with VITAL-NET for Japan.
ACCRUFeR®/FeRACCRU® has patent coverage until the mid-2030s.
ACCRUFeR®/FeRACCRU® are registered trademarks of Shield Therapeutics.